Summary & Overview
CPT 80348: Buprenorphine Detection and Quantification
Headline: CPT code 80348 defines laboratory testing for buprenorphine detection, a key component of opioid use disorder care and select pain management.
Lead: CPT code 80348 represents laboratory assays that detect or quantify buprenorphine in patient specimens. This testing supports monitoring of medication adherence, safety, and treatment planning for patients receiving buprenorphine for opioid dependence or specific pain indications.
Why it matters: Buprenorphine testing is clinically important amid a national focus on opioid use disorder treatment access and quality. Reliable laboratory detection informs medication-assisted treatment programs, outpatient clinics, and hospital care teams, influencing clinical decision-making and regulatory compliance.
Key payers covered: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: This publication provides a concise overview of CPT code 80348, including clinical context for buprenorphine testing, typical sites of service and service type, payer coverage considerations, and common billing modifiers. It summarizes available benchmarks and highlights policy-relevant issues such as coverage variability and coding accuracy. Practical information is offered on documentation expectations and where to look for payer-specific billing guidance.
Scope: Content is written for a national audience of clinicians, laboratory managers, and billing professionals seeking a clear, policy-focused summary of CPT code 80348.
Billing Code Overview
CPT code 80348 covers laboratory testing to measure the amount of, or detect the presence of, buprenorphine in a patient specimen. Buprenorphine is a medication used to treat opioid use disorder and to manage certain types of pain when full opioid therapy is inappropriate.
Service Type: Drug testing / Therapeutic drug monitoring
Typical Site of Service: Clinical laboratory, hospital laboratory, outpatient laboratory, addiction treatment clinic
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient enrolled in an office-based opioid treatment program presents for routine monitoring after initiation of buprenorphine therapy for opioid use disorder. A urine specimen is collected at the clinic visit and sent to the laboratory to detect the presence of buprenorphine and its metabolites to confirm adherence, evaluate diversion, and guide ongoing treatment. The clinical workflow: collection of the specimen under chain-of-custody or observed conditions as required, transport to a clinical laboratory, analyst performs a qualitative or quantitative immunoassay or chromatographic confirmation for buprenorphine, result reported to the treating clinician, and the clinician documents findings in the medical record and adjusts treatment or counseling as indicated. Typical sites of service include outpatient addiction medicine clinics, ambulatory care centers, hospital outpatient laboratories, and federally qualified health centers. The service is commonly ordered for patients receiving buprenorphine for opioid use disorder, for suspected nonadherence or diversion, or for pain management when buprenorphine is prescribed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard reporting | Use when no special circumstances apply. |
26 |